NCT06553027: To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
- State
- Under way
- Phase
- Phase 3
- People
- 330 planned
- Started
- 20 Sep 2024
- Primary completion
- Aug 2026
- Arms
- CVN424 75 mg
- Results
- None posted
- 14 Aug 2024: Trial registered
- 20 Sep 2024: Trial started